{
    "Disease activity (follow up: 1 year; assessed with: DAS 44 (Lower values – > benefit) (MCID -1.2 based on the EULAR criteria)": {
      "No of studies": ["1", "2"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": "not serious",
      "Other considerations": "none",
      "No of patients": {
        "csDMARD double therapy": ["104","b"],
        "csDMARD monotherapy": ["206","c"]
      },
      "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 0.3 lower (0.57 lower to 0.02 higher)"
      },
      "Certainty": "MODERATE",
      "Importance": "CRITICAL"
    },
    "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)": {
      "No of studies": ["1", "2"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": "not serious",
      "Other considerations": "none",
      "No of patients": {
        "csDMARD double therapy": ["104","b"],
        "csDMARD monotherapy": ["206","c"]
      },
      "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 0.01 lower (0.16 lower to 0.14 higher)"
      },
      "Certainty": "MODERATE",
      "Importance": "IMPORTANT"
    },
    "Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)": {
      "No of studies": ["2"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "d"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["serious", "e"],
      "Other considerations": "none",
      "No of patients": {
        "csDMARD double therapy": ["36","b"],
        "csDMARD monotherapy": ["69","c"]
      },
      "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 0.05 higher (10.89 lower to 10.99 higher)"
      },
      "Certainty": "LOW",
      "Importance": "IMPORTANT"
    },
    "Serious adverse events (follow up: 1 year)": {
      "No of studies": ["2"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "d"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["very serious", "f"],
      "Other considerations": "none",
      "No of patients": {
        "csDMARD double therapy": ["0/36 (0.0%)", "b"],
        "csDMARD monotherapy": ["3/69 (4.3%)", "c"]
      },
      "Effect": {
        "Relative (95% CI)": "RR 0.27 (0.01 to 5.09)",
        "Absolute (95% CI)": "32 fewer per 1,000 (from 43 fewer to 178 more)"
      },
      "Certainty": "VERY LOW",
      "Importance": "IMPORTANT"
    },
    "Withdrawal due to lack of efficacy (follow up: 1 year)": {
      "No of studies": ["1", "2"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["very serious", "f"],
      "Other considerations": "none",
      "No of patients": {
        "csDMARD double therapy": ["4/104 (3.8%)", "b"],
        "csDMARD monotherapy": ["15/206 (7.3%)", "c"]
      },
      "Effect": {
        "Relative (95% CI)": "RR 0.53 (0.18 to 1.56)",
        "Absolute (95% CI)": "34 fewer per 1,000 (from 60 fewer to 41 more)"
      },
      "Certainty": "VERY LOW",
      "Importance": "IMPORTANT"
    },
    "Withdrawal due to Adverse events (follow up: 1 year)": {
      "No of studies": ["1", "2"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["very serious", "f"],
      "Other considerations": "none",
      "No of patients": {
        "csDMARD double therapy": ["14/104 (13.5%)", "b"],
        "csDMARD monotherapy": ["28/206 (13.6%)", "c"]
      },
      "Effect": {
        "Relative (95% CI)": "RR 0.99 (0.54 to 1.79)",
        "Absolute (95% CI)": "1 fewer per 1,000 (from 63 fewer to 107 more)"
      },
      "Certainty": "VERY LOW",
      "Importance": "IMPORTANT"
    }
  }